DK0912558T3 - Substituerede indazolderivater og deres anvendelse som inhibitorer af phosphodiesterase (PDE) type IV og tumornekrosefaktor (TNF) - Google Patents

Substituerede indazolderivater og deres anvendelse som inhibitorer af phosphodiesterase (PDE) type IV og tumornekrosefaktor (TNF)

Info

Publication number
DK0912558T3
DK0912558T3 DK97921992T DK97921992T DK0912558T3 DK 0912558 T3 DK0912558 T3 DK 0912558T3 DK 97921992 T DK97921992 T DK 97921992T DK 97921992 T DK97921992 T DK 97921992T DK 0912558 T3 DK0912558 T3 DK 0912558T3
Authority
DK
Denmark
Prior art keywords
pde
phosphodiesterase
tnf
inhibitors
type
Prior art date
Application number
DK97921992T
Other languages
Danish (da)
English (en)
Inventor
Anthony Marfat
Original Assignee
Pfizer
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pfizer filed Critical Pfizer
Application granted granted Critical
Publication of DK0912558T3 publication Critical patent/DK0912558T3/da

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/415—1,2-Diazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pain & Pain Management (AREA)
  • Communicable Diseases (AREA)
  • Obesity (AREA)
  • Immunology (AREA)
  • Hematology (AREA)
  • Oncology (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Dermatology (AREA)
  • Diabetes (AREA)
  • Rheumatology (AREA)
  • Neurosurgery (AREA)
  • Urology & Nephrology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Pulmonology (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
DK97921992T 1996-06-25 1997-06-02 Substituerede indazolderivater og deres anvendelse som inhibitorer af phosphodiesterase (PDE) type IV og tumornekrosefaktor (TNF) DK0912558T3 (da)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US2038596P 1996-06-25 1996-06-25
PCT/IB1997/000630 WO1997049702A1 (en) 1996-06-25 1997-06-02 Substituted indazole derivatives and their use as phosphodiesterase (pde) type iv and tumor necrosis factor (tnf) inhibitors

Publications (1)

Publication Number Publication Date
DK0912558T3 true DK0912558T3 (da) 2003-08-18

Family

ID=21798354

Family Applications (1)

Application Number Title Priority Date Filing Date
DK97921992T DK0912558T3 (da) 1996-06-25 1997-06-02 Substituerede indazolderivater og deres anvendelse som inhibitorer af phosphodiesterase (PDE) type IV og tumornekrosefaktor (TNF)

Country Status (43)

Country Link
US (1) US6040329A (sh)
EP (1) EP0912558B1 (sh)
JP (1) JP3152940B2 (sh)
KR (1) KR20000022516A (sh)
CN (1) CN1080260C (sh)
AP (1) AP1025A (sh)
AR (1) AR007456A1 (sh)
AT (1) ATE244713T1 (sh)
AU (1) AU716376B2 (sh)
BG (1) BG64052B1 (sh)
BR (1) BR9712782A (sh)
CA (1) CA2258285C (sh)
CO (1) CO4900056A1 (sh)
CZ (1) CZ423398A3 (sh)
DE (1) DE69723447T2 (sh)
DK (1) DK0912558T3 (sh)
DZ (1) DZ2254A1 (sh)
EA (1) EA002274B1 (sh)
ES (1) ES2201299T3 (sh)
GT (1) GT199700075A (sh)
HK (1) HK1018700A1 (sh)
HN (1) HN1997000079A (sh)
HR (1) HRP970350B1 (sh)
HU (1) HUP9903009A3 (sh)
ID (1) ID18579A (sh)
IL (1) IL127036A (sh)
IS (1) IS4910A (sh)
MA (1) MA24225A1 (sh)
MY (1) MY116915A (sh)
NO (1) NO986103D0 (sh)
NZ (1) NZ332752A (sh)
OA (1) OA10934A (sh)
PA (1) PA8432301A1 (sh)
PL (1) PL330974A1 (sh)
PT (1) PT912558E (sh)
SI (1) SI0912558T1 (sh)
SK (1) SK176598A3 (sh)
TN (1) TNSN97108A1 (sh)
TR (1) TR199802685T2 (sh)
TW (1) TW434237B (sh)
WO (1) WO1997049702A1 (sh)
YU (1) YU60198A (sh)
ZA (1) ZA975581B (sh)

Families Citing this family (38)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1997048697A1 (en) 1996-06-19 1997-12-24 Rhone-Poulenc Rorer Limited Substituted azabicylic compounds and their use as inhibitors of the production of tnf and cyclic amp phosphodiesterase
YU11299A (sh) * 1996-09-04 2001-07-10 Pfizer Inc. Derivati indazola
US6248746B1 (en) 1998-01-07 2001-06-19 Euro-Celtique S.A. 3-(arylalkyl) xanthines
CA2309175A1 (en) * 1997-11-04 1999-05-14 Pfizer Products Inc. Therapeutically active compounds based on indazole bioisostere replacement of catechol in pde4 inhibitors
ATE290002T1 (de) * 1999-12-23 2005-03-15 Icos Corp Cyclische amp spezifische phosphodiesterase inhibitoren
US6362213B1 (en) 1999-12-23 2002-03-26 Icos Corporation Cyclic AMP-specific phosphodiesterase inhibitors
US6953774B2 (en) 2000-08-11 2005-10-11 Applied Research Systems Ars Holding N.V. Methods of inducing ovulation
US7205320B2 (en) 2001-01-22 2007-04-17 Memory Pharmaceuticals Corp. Phosphodiesterase 4 inhibitors
US7153871B2 (en) 2001-01-22 2006-12-26 Memory Pharmaceuticals Corporation Phosphodiesterase 4 inhibitors, including aminoindazole and aminobenzofuran analogs
US6982274B2 (en) * 2001-04-16 2006-01-03 Eisai Co., Ltd. 1H-indazole compound
PT1908463E (pt) 2001-12-14 2011-12-19 Merck Serono Sa Método para induzir a ovulação utilizando um modulador de nível camp não polipeptídico
BR0313000A (pt) 2002-07-19 2005-07-12 Memory Pharm Corp Compostos, composição farmacêutica e método para efetuar a inibição da enzima pde4, realçar a cognição e/ou tratar a psicose em um paciente
NZ537724A (en) 2002-07-19 2006-10-27 Memory Pharm Corp Phosphodiesterase 4 inhibitors, including N-substituted aniline and diphenylamine analogs
BR0315705A (pt) * 2002-11-19 2005-09-06 Memory Pharm Corp Inibidores de fosfodiesterase-4
WO2004094411A1 (en) * 2003-04-18 2004-11-04 Memory Pharmaceuticals Corporation Pyrazole derivatives as phosphodiesterase 4 inhibitors
US20090048255A1 (en) * 2003-07-21 2009-02-19 Schumacher Richard A Phosphodiesterase 4 inhibitors, including n-substituted aniline and diphenylamine analogs
MY141255A (en) * 2003-12-11 2010-03-31 Memory Pharm Corp Phosphodiesterase 4 inhibitors, including n-substituted diarylamine analogs
WO2006044528A1 (en) * 2004-10-15 2006-04-27 Memory Pharmaceuticals Corporation Pyrazole derivatives as phosphodiesterase 4 inhibitors
US7601847B2 (en) 2004-10-26 2009-10-13 Wyeth Preparation and purification of 4-(indazol-3-yl)phenols
WO2006129158A2 (en) * 2005-05-30 2006-12-07 Ranbaxy Laboratories Limited 3 - indazolyl - isoxazoline derivatives as inhibitors of phosphodiesterase type - i
EP2258359A3 (en) 2005-08-26 2011-04-06 Braincells, Inc. Neurogenesis by muscarinic receptor modulation with sabcomelin
JP2009506069A (ja) 2005-08-26 2009-02-12 ブレインセルス，インコーポレイティド ムスカリン性受容体調節による神経発生
US7781460B2 (en) 2005-09-05 2010-08-24 Ranbaxy Laboratories Limited Substituted indazoles as inhibitors of phosphodiesterase type-IV
WO2007031838A1 (en) 2005-09-16 2007-03-22 Ranbaxy Laboratories Limited Substituted pyrazolo [3,4-b] pyridines as phosphodiesterase inhibitors
CA2625153A1 (en) 2005-10-21 2007-04-26 Braincells, Inc. Modulation of neurogenesis by pde inhibition
US20070112017A1 (en) 2005-10-31 2007-05-17 Braincells, Inc. Gaba receptor mediated modulation of neurogenesis
US20100216734A1 (en) 2006-03-08 2010-08-26 Braincells, Inc. Modulation of neurogenesis by nootropic agents
EP2377531A2 (en) 2006-05-09 2011-10-19 Braincells, Inc. Neurogenesis by modulating angiotensin
US20100184806A1 (en) 2006-09-19 2010-07-22 Braincells, Inc. Modulation of neurogenesis by ppar agents
MX2009009793A (es) 2007-03-14 2009-10-16 Ranbaxy Lab Ltd Derivados de pirazolo (3,4-b) piridina como inhibidores de fosfodiesterasa.
US20100029689A1 (en) * 2008-07-02 2010-02-04 Memory Pharmaceuticals Corporation Phosphodiesterase 4 inhibitors
US20100216805A1 (en) 2009-02-25 2010-08-26 Braincells, Inc. Modulation of neurogenesis using d-cycloserine combinations
NZ599597A (en) * 2009-10-30 2013-05-31 Janssen Pharmaceutica Nv IMIDAZO[1,2-b]PYRIDAZINE DERIVATIVES AND THEIR USE AS PDE10 INHIBITORS
WO2013106547A1 (en) 2012-01-10 2013-07-18 President And Fellows Of Harvard College Beta-cell replication promoting compounds and methods of their use
US20150125438A1 (en) * 2012-07-20 2015-05-07 Sang Jae Kim Anti-Inflammatory Peptides and Composition Comprising the Same
WO2015166370A1 (en) 2014-04-28 2015-11-05 Pfizer Inc. Heteroaromatic compounds and their use as dopamine d1 ligands
KR20220167441A (ko) * 2021-06-11 2022-12-21 주식회사 메타센테라퓨틱스 신규한 인돌 유도체 및 이의 최종당화산물 관련 질환의 치료 용도
KR20220167804A (ko) * 2021-06-11 2022-12-22 주식회사 메타센테라퓨틱스 인돌 유도체를 포함하는 최종당화산물 관련 질환의 치료용 조성물

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB753573A (en) * 1953-06-17 1956-07-25 Ici Ltd New dyestuffs intermediates
GB8707051D0 (en) * 1986-04-15 1987-04-29 Ici America Inc Heterocyclic carboxamides
PT100441A (pt) * 1991-05-02 1993-09-30 Smithkline Beecham Corp Pirrolidinonas, seu processo de preparacao, composicoes farmaceuticas que as contem e uso
TW223004B (sh) * 1991-11-25 1994-05-01 Sumitomo Chemical Co
US5444038A (en) * 1992-03-09 1995-08-22 Zeneca Limited Arylindazoles and their use as herbicides
AU677776B2 (en) * 1992-04-02 1997-05-08 Smithkline Beecham Corporation Compounds useful for treating allergic and inflammatory diseases
US5612360A (en) * 1992-06-03 1997-03-18 Eli Lilly And Company Angiotensin II antagonists
US5554620A (en) * 1993-09-14 1996-09-10 Sterling Winthrop Inc. Substituted 6,11-ethano-6,11-dihydrobenzo[b] quinolizinium salts and compositions and methods of use thereof
JPH07215952A (ja) * 1993-12-06 1995-08-15 Otsuka Pharmaceut Factory Inc カテコール誘導体
WO1996012720A1 (en) * 1994-10-20 1996-05-02 Pfizer Inc. Bicyclic tetrahydro pyrazolopyridines and their use as medicaments

Also Published As

Publication number Publication date
MY116915A (en) 2004-04-30
CA2258285C (en) 2002-11-26
PL330974A1 (en) 1999-06-21
OA10934A (en) 2002-02-18
CZ423398A3 (cs) 1999-12-15
ATE244713T1 (de) 2003-07-15
MA24225A1 (fr) 1997-12-31
CO4900056A1 (es) 2000-03-27
EA002274B1 (ru) 2002-02-28
NZ332752A (en) 2001-04-27
PA8432301A1 (es) 1999-12-27
HK1018700A1 (en) 1999-12-30
HN1997000079A (es) 1997-12-26
TW434237B (en) 2001-05-16
YU60198A (sh) 1999-09-27
AR007456A1 (es) 1999-10-27
PT912558E (pt) 2003-11-28
HRP970350B1 (en) 2003-04-30
IS4910A (is) 1998-11-27
BR9712782A (pt) 1999-12-07
HUP9903009A2 (hu) 2000-05-28
US6040329A (en) 2000-03-21
JP3152940B2 (ja) 2001-04-03
NO986103L (no) 1998-12-23
JPH11514668A (ja) 1999-12-14
GT199700075A (es) 1998-12-04
DZ2254A1 (fr) 2002-12-18
BG64052B1 (bg) 2003-11-28
ID18579A (id) 1998-04-23
AP1025A (en) 2001-11-19
HUP9903009A3 (en) 2002-01-28
EA199801047A1 (ru) 1999-06-24
WO1997049702A1 (en) 1997-12-31
NO986103D0 (no) 1998-12-23
TR199802685T2 (xx) 1999-03-22
HRP970350A2 (en) 1998-06-30
SI0912558T1 (en) 2003-10-31
DE69723447D1 (de) 2003-08-14
EP0912558A1 (en) 1999-05-06
AU716376B2 (en) 2000-02-24
ES2201299T3 (es) 2004-03-16
AP9701020A0 (en) 1997-07-31
CA2258285A1 (en) 1997-12-31
CN1223651A (zh) 1999-07-21
DE69723447T2 (de) 2003-12-24
ZA975581B (en) 1998-12-24
IL127036A (en) 2001-06-14
AU2785797A (en) 1998-01-14
CN1080260C (zh) 2002-03-06
SK176598A3 (en) 2000-06-12
EP0912558B1 (en) 2003-07-09
TNSN97108A1 (fr) 2005-03-15
KR20000022516A (ko) 2000-04-25
IL127036A0 (en) 1999-09-22
BG103056A (en) 1999-10-29

Similar Documents

Publication Publication Date Title
DK0912558T3 (da) Substituerede indazolderivater og deres anvendelse som inhibitorer af phosphodiesterase (PDE) type IV og tumornekrosefaktor (TNF)
NO991048D0 (no) Indazolderivater og deres anvendelse som inhibitorer av fosfodiesterase (PDE) type IV og fremstillingen av tumornekrosefaktor (TNF)
NO985095D0 (no) Substituerte indazolderivater og deres anvendelse som inhibitorer fosfodiesterase (PDE) type IV og produksjon av tumornekrosefaktor (TNF)
DK1475377T3 (da) Indol-derivater og deres anvendelse som inhibitorer for phosphodiesterase 4
DK1000039T3 (da) Substituerede quinazolinderivater og anvendelse deraf som tyrosinkinaseinhibitorer
NO20026010D0 (no) Substituerte quinazolinderivater og deres anvendelse som inhibitorer
NO20001102L (no) 2,3-diaryl-pyrazolo[1,5-B]pyridazinderivater, deres fremstilling og anvendelse som cyklo-oksygenase 2 (COX-2) inhibitorer
DK1480962T3 (da) 5-Phenylthiazol-derivater og deres anvendelse som P1-3-kinaseinhibitorer
DK0810218T3 (da) 6-benzyl-2H-pyridazin-3-onderivater samt fremstilling og anvendelsen deraf som inhibitorer af prostaglandin-G/H-syntase I og II (COX I og COX II)
NO20030958L (no) Pyrazolderivater og deres anvendelse som proteinkinase inhibitorer
AU2001288374A1 (en) Substituted oxindole derivatives as tyrosine kinase inhibitors
AU2002226911A1 (en) Indol derivative and their use as inhibitors of p38 kinase
PT934280E (pt) Derivados 2-cianoiminoimidazolo inibidores da pde iv
DK0983249T3 (da) Fremgangsmåder og mellemprodukter til fremstilling af substituerede indazolderivater
NO20003199D0 (no) Benzo(C)kinolizinderivater og deres anvendelse som 5- <alfa>reduktaseinhibitorer
DK1066284T3 (da) Benzo(C)quinolizinderivater og deres anvendelse som 5-alpha-reduktaseinhibitorer